UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3647) 3647
Book Chapter (135) 135
Dissertation (6) 6
Magazine Article (2) 2
Conference Proceeding (1) 1
Newsletter (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (2822) 2822
life sciences & biomedicine (2732) 2732
female (2600) 2600
humans (2509) 2509
breast neoplasms - drug therapy (1376) 1376
breast cancer (1284) 1284
aromatase inhibitors (1186) 1186
oncology (1125) 1125
animals (1004) 1004
aromatase inhibitors - therapeutic use (895) 895
aromatase (838) 838
middle aged (821) 821
male (805) 805
aromatase inhibitors - administration & dosage (670) 670
aged (662) 662
estrogen (632) 632
adult (621) 621
aromatase inhibitor (546) 546
tamoxifen (546) 546
breast neoplasms - pathology (528) 528
cancer (502) 502
endocrinology & metabolism (500) 500
postmenopause (487) 487
antineoplastic agents, hormonal - therapeutic use (467) 467
aromatase inhibitors - adverse effects (466) 466
treatment outcome (446) 446
triazoles - administration & dosage (444) 444
nitriles - administration & dosage (440) 440
aromatase - metabolism (439) 439
letrozole (438) 438
obstetrics & gynecology (429) 429
care and treatment (414) 414
medicine & public health (409) 409
tamoxifen - therapeutic use (406) 406
aromatase inhibitors - pharmacology (396) 396
triazoles - therapeutic use (393) 393
nitriles - therapeutic use (386) 386
chemotherapy, adjuvant (366) 366
postmenopausal women (328) 328
rats (320) 320
tamoxifen - administration & dosage (308) 308
research (307) 307
antineoplastic agents, hormonal - administration & dosage (292) 292
analysis (287) 287
health aspects (287) 287
pharmacology & pharmacy (286) 286
abridged index medicus (283) 283
aromatase - genetics (282) 282
estradiol (272) 272
endocrine therapy (271) 271
breast neoplasms - metabolism (270) 270
estradiol - blood (270) 270
testosterone (268) 268
aged, 80 and over (267) 267
antineoplastic combined chemotherapy protocols - therapeutic use (266) 266
drug therapy (264) 264
anastrozole (263) 263
reproductive biology (262) 262
triazoles - pharmacology (261) 261
pregnancy (248) 248
estrogens (240) 240
nitriles - pharmacology (236) 236
drug administration schedule (228) 228
mice (225) 225
chemotherapy (224) 224
antineoplastic agents - therapeutic use (223) 223
internal medicine (214) 214
disease-free survival (209) 209
antineoplastic agents, hormonal - adverse effects (206) 206
clinical trials (205) 205
dose-response relationship, drug (205) 205
menopause (205) 205
nitriles - adverse effects (200) 200
triazoles - adverse effects (200) 200
neurosciences (194) 194
risk factors (194) 194
receptors, estrogen - metabolism (193) 193
hormones (191) 191
neurosciences & neurology (190) 190
time factors (185) 185
breast neoplasms - mortality (184) 184
clinical trials as topic (176) 176
obstetrics and gynecology (176) 176
randomized controlled trials as topic (175) 175
androgens (171) 171
neoplasm staging (170) 170
testosterone - blood (169) 169
gene expression (167) 167
biochemistry & molecular biology (164) 164
estradiol - pharmacology (163) 163
hematology, oncology and palliative medicine (163) 163
womens health (156) 156
metastasis (152) 152
enzymes (151) 151
exemestane (150) 150
double-blind method (146) 146
tamoxifen - adverse effects (146) 146
cancer therapies (143) 143
enzyme inhibitors - pharmacology (141) 141
breast neoplasms - genetics (140) 140
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3672) 3672
Japanese (52) 52
French (28) 28
German (27) 27
Russian (11) 11
Italian (10) 10
Chinese (7) 7
Hungarian (7) 7
Norwegian (5) 5
Portuguese (4) 4
Danish (3) 3
Spanish (3) 3
Arabic (2) 2
Bulgarian (2) 2
Dutch (2) 2
Polish (2) 2
Swedish (2) 2
Finnish (1) 1
Hebrew (1) 1
Korean (1) 1
Romanian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The lancet oncology, ISSN 1470-2045, 01/2015, Volume 16, Issue 1, pp. 25 - 35
Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Triazoles - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Molecular Targeted Therapy | North America | Nitriles - administration & dosage | Breast Neoplasms - enzymology | Time Factors | Postmenopause | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Republic of Korea | Aromatase Inhibitors - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Europe | Proportional Hazards Models | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Cyclin D1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | South Africa | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Research | Antineoplastic agents | Phosphotransferases | Cancer | Index Medicus
Journal Article
Journal of bone and mineral metabolism, ISSN 0914-8779, 11/2018, Volume 36, Issue 6, pp. 716 - 722
Although adjuvant aromatase inhibitor (AI) therapy is widely used in postmenopausal women with hormone receptor-positive breast cancer, it is known to be associated with bone loss and increased fracture risk... 
Aromatase inhibitor | Medicine & Public Health | Orthopedics | Metabolic Diseases | Breast cancer | Bone mineral density | Denosumab | Endocrinology & Metabolism | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Biomarkers - metabolism | Postmenopause - drug effects | Adjuvants, Pharmaceutic - pharmacology | Humans | Japan | Middle Aged | Alkaline Phosphatase - metabolism | Bone Density Conservation Agents - therapeutic use | Osteoporotic Fractures - drug therapy | Denosumab - adverse effects | Breast Neoplasms - drug therapy | Bone Remodeling - drug effects | Denosumab - therapeutic use | Asian Continental Ancestry Group | Bone Density - drug effects | Denosumab - administration & dosage | Adjuvants, Pharmaceutic - therapeutic use | Tartrate-Resistant Acid Phosphatase - metabolism | Aged, 80 and over | Female | Aged | Aromatase Inhibitors - therapeutic use | Medical colleges | Surgical clinics | Adjuvant treatment | Calcifediol | Postmenopausal women | Metastasis | Density | Osteoporosis | Vitamin D | Monoclonal antibodies | Bones | Alfacalcidol | Cancer | Jaw | Femur | Calcium | Spine (lumbar) | Osteonecrosis | Post-menopause | Metastases | Bone cancer | Bone mass | Fractures | Aromatase | Hormone replacement therapy | Bone density | Bone loss | Hypocalcemia | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 07/2016, Volume 375, Issue 3, pp. 209 - 219
Journal Article
Clinical cancer research, ISSN 1557-3265, 01/2017, Volume 23, Issue 1, pp. 26 - 34
Purpose: Alpelisib, a selective oral inhibitor of the class I PI3K catalytic subunit p110 alpha, has shown synergistic antitumor activity with endocrine therapy againstER... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Triazoles - administration & dosage | Receptors, Estrogen - metabolism | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Thiazoles - administration & dosage | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Biomarkers, Tumor | Breast Neoplasms - metabolism | Nitriles - administration & dosage | Neoplasm Metastasis | DNA Mutational Analysis | Adult | Female | Aromatase Inhibitors - administration & dosage | Receptors, Estrogen - genetics | In Situ Hybridization, Fluorescence | Treatment Outcome | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Maximum Tolerated Dose | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Cell Line, Tumor | Aged | Mutation | Neoplasm Staging | Letrozole | Therapy | Toxicity | p53 Protein | Exanthema | Clinical trials | Metastasis | K-Ras protein | Metastases | Gene sequencing | Anticancer properties | Hyperglycemia | Catalysis | Fibroblast growth factor receptor 1 | Deoxyribonucleic acid--DNA | Diarrhea | Endocrine therapy | Fatigue | Nausea | Breast cancer | Patients | ErbB-2 protein | 1-Phosphatidylinositol 3-kinase | Inhibitors | Experimental design | Antitumor activity | Tumors | DNA sequencing | Cancer | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 386, Issue 10001, pp. 1341 - 1352
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2010, Volume 28, Issue 31, pp. 4674 - 4682
Journal Article
Journal Article
Journal Article